Literature DB >> 16515590

Methylation of death-associated protein kinase in ovarian carcinomas.

Y Collins1, R Dicioccio, B Keitz, S Lele, K Odunsi.   

Abstract

Death-associated protein (DAP) kinase is a serine/threonine kinase that plays an integral role in apoptosis and metastasis. The purpose of our study was to determine the methylation status of DAP kinase in ovarian carcinomas. Thirty-one patients with histologically confirmed epithelial ovarian cancers treated at Roswell Park Cancer Institute, Buffalo, New York, between 1987 and 1999 were studied. Sixty-two samples were examined for DAP kinase methylation status: 1 normal human genomic DNA sample from a healthy individual, 1 transformed normal surface ovarian epithelial cell line (IOSE, from Dr Nancy Auersperg, Vancouver, Canada), 2 ovarian carcinoma cell lines (OVCAR3 and A2780), 1 ovarian serous cystadenoma, and 30 ovarian carcinomas. Additionally, peripheral blood DNA was examined from the patients with the serous cystadenoma and ovarian carcinomas. Methylation-specific polymerase chain reaction was performed using primers designed for the unmethylated and methylated promoter regions. The DAP kinase gene was unmethylated in both the normal human genomic DNA sample and the transformed normal surface epithelial ovarian cell line. The two ovarian cancer cell lines were methylated. In the 30 patients with malignant disease, methylation of DAP kinase was observed in 20 (67%). Peripheral blood DNA was available in 26 (87%) of the 30 patients. Comparison of the paired samples indicated that 14 (54%) were methylated and 12 (46%) were unmethylated. There was no correlation between the DAP kinase methylation status and stage, grade, histology, or survival. Methylation of CpG islands in the promoter region of the DAP kinase gene is common in peripheral blood DNA and tissue samples of patients with ovarian carcinomas. This molecular aberration may represent a potential target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16515590     DOI: 10.1111/j.1525-1438.2006.00506.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  12 in total

1.  Ser289 phosphorylation activates both DAPK1 and DAPK2 but in response to different intracellular signaling pathways.

Authors:  Ruth Shiloh; Shani Bialik; Adi Kimchi
Journal:  Cell Cycle       Date:  2019-05-22       Impact factor: 4.534

Review 2.  Epigenomics and ovarian carcinoma.

Authors:  Leonel Maldonado; Mohammad Obaidul Hoque
Journal:  Biomark Med       Date:  2010-08       Impact factor: 2.851

3.  Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes.

Authors:  Liguo Zhang; Kenneth P Nephew; Patricia J Gallagher
Journal:  J Biol Chem       Date:  2007-02-26       Impact factor: 5.157

4.  Epigenetic Silencing of DAPK1and p16 INK4a Genes by CpG Island Hypermethylation in Epithelial Ovarian Cancer Patients.

Authors:  Mariyam Zuberi; Sagar Dholariya; Imran Khan; Rashid Mir; Sameer Guru; Musadiq Bhat; Mamta Sumi; Alpana Saxena
Journal:  Indian J Clin Biochem       Date:  2020-05-16

5.  Epigenomics of ovarian cancer and its chemoprevention.

Authors:  Huaping Chen; Tabitha M Hardy; Trygve O Tollefsbol
Journal:  Front Genet       Date:  2011-10-04       Impact factor: 4.599

Review 6.  Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?

Authors:  Ha T Nguyen; Geng Tian; Mandi M Murph
Journal:  Front Oncol       Date:  2014-04-08       Impact factor: 6.244

7.  Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review).

Authors:  Chiharu Uekuri; Hiroshi Shigetomi; Sumire Ono; Yoshikazu Sasaki; Miyuki Matsuura; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2013-08-28       Impact factor: 2.967

8.  NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.

Authors:  Vladimir Kashuba; Alexey A Dmitriev; George S Krasnov; Tatiana Pavlova; Ilya Ignatjev; Vasily V Gordiyuk; Anna V Gerashchenko; Eleonora A Braga; Surya P Yenamandra; Michael Lerman; Vera N Senchenko; Eugene Zabarovsky
Journal:  Int J Mol Sci       Date:  2012-10-18       Impact factor: 5.923

Review 9.  DAPK1 Promoter Methylation and Cervical Cancer Risk: A Systematic Review and a Meta-Analysis.

Authors:  Antonella Agodi; Martina Barchitta; Annalisa Quattrocchi; Andrea Maugeri; Manlio Vinciguerra
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

10.  Big data-based identification of methylated genes associated with drug resistance and prognosis in ovarian cancer.

Authors:  Bingbing Yan; Chunqiu Xiong; Feifeng Huang; Mingming Zhang; Yan Mo; Hua Bai
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.